Related Experiment Video

Updated: Nov 5, 2025

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.6K

ATR Inhibition as an Attractive Therapeutic Resource against Cancer

Antoine Italiano1

  • 1Early Phase Trials Unit, Institut Bergonié, Bordeaux, France. DITEP, Gustave Roussy, Villejuif, France. University of Bordeaux, Bordeaux, France. a.italiano@bordeaux.unicancer.fr antoine.italiano@gustaveroussy.fr.

Cancer Discovery
|May 18, 2021
PubMed

Insights

A new drug, BAY 1895344, shows safety and effectiveness in treating advanced solid tumors with ATM deficiency. This potent ATR inhibitor induces durable responses, opening doors for new cancer treatment combinations.

Area of Science:

  • Oncology
  • Clinical Pharmacology
  • Cancer Therapeutics

Background:

  • DNA damage response (DDR) pathways are crucial for cancer cell survival.
  • ATM (ataxia-telangiectasia mutated) is a key kinase in the DDR pathway.
  • Targeting DDR defects presents a promising strategy for cancer treatment.

Purpose of the Study:

  • To evaluate the safety and efficacy of BAY 1895344, a novel ATR inhibitor.
  • To assess the clinical activity of BAY 1895344 in patients with advanced solid tumors, particularly those with ATM deficiency.

Main Methods:

  • Phase I clinical trial.
  • Enrollment of 22 patients with advanced solid tumors.
  • Administration of BAY 1895344, a potent and specific ATR inhibitor.

Main Results:

  • BAY 1895344 demonstrated a safe profile in the studied patient cohort.
  • The drug induced durable responses in patients with ATM-deficient tumors.
  • Compelling clinical activity was observed, supporting further investigation.

Conclusions:

  • BAY 1895344 is a safe and effective ATR inhibitor for ATM-deficient tumors.
  • This finding supports the development of combination therapies targeting DNA damage response defects.
  • Further research into novel combination regimens is warranted.

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.9K
An In Vitro Enzymatic Assay to Measure Transcription Inhibition by GalliumIII and H3 5,10,15-trispentafluorophenylcorroles09:00

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by GalliumIII and H3 5,10,15-trispentafluorophenylcorroles

Published on: March 18, 2015

11.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.4K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
801
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.2K